electroCore (NASDAQ:ECOR) Given “Buy” Rating at Brookline Capital Management

Brookline Capital Management reaffirmed their buy rating on shares of electroCore (NASDAQ:ECOR – Get Rating) in a research note issued to investors on Thursday, PriceTargets.com reports.

Several other research firms also recently issued reports on ECOR. Berenberg Bank lowered their price objective on electroCore from GBX 390 ($4.75) to GBX 330 ($4.02) and set a buy rating for the company in a research note on Thursday, October 6th. Brookline Capital Acquisition began coverage on shares of electroCore in a research report on Friday. They set a buy rating for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $111.42.

electroCore Price Performance

NASDAQ:ECOR opened at $0.30 on Thursday. electroCore has a one year low of $0.20 and a one year high of $0.90. The company has a market cap of $21.49 million, a P/E ratio of -0.97 and a beta of 0.93. The firm’s fifty day moving average price is $0.30 and its two-hundred day moving average price is $7.80.

electroCore (NASDAQ:ECOR – Get Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). electroCore had a negative net margin of 283.41% and a negative return on equity of 72.36%. The business had revenue of $1.98 million during the quarter. As a group, equities research analysts expect that electroCore will post -0.3 earnings per share for the current year.

Insider Buying and Selling at electroCore

In other electroCore news, Director Joseph P. Errico purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, December 13th. The stock was purchased at an average price of $0.33 per share, for a total transaction of $33,000.00. Following the transaction, the director now owns 2,724,841 shares in the company, valued at approximately $899,197.53. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders purchased 670,000 shares of company stock valued at $186,650 in the last quarter. 13.11% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On electroCore

Hedge funds have recently made changes to their positions in the business. AWM Investment Company Inc. lifted its holdings in shares of electroCore by 18.0% during the second quarter. AWM Investment Company Inc. now owns 5,493,876 shares of the company’s stock valued at $2,801,000 after purchasing an additional 838,129 shares in the last quarter. Valeo Financial Advisors LLC increased its position in electroCore by 1.2% in the second quarter. Valeo Financial Advisors LLC now owns 1,844,500 shares of the company’s stock worth $941,000 after buying an additional 22,250 shares in the last quarter. Wealthspire Advisors LLC increased its position in electroCore by 40.0% in the second quarter. Wealthspire Advisors LLC now owns 700,000 shares of the company’s stock worth $357,000 after buying an additional 200,000 shares in the last quarter. Jaffetilchin Investment Partners LLC increased its position in electroCore by 31.6% in the first quarter. Jaffetilchin Investment Partners LLC now owns 307,984 shares of the company’s stock worth $82,000 after buying an additional 74,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of electroCore by 102.2% during the second quarter. Renaissance Technologies LLC now owns 262,848 shares of the company’s stock worth $134,000 after purchasing an additional 132,848 shares in the last quarter. 17.76% of the stock is owned by hedge funds and other institutional investors.

About electroCore

(Get Rating)

electroCore, Inc, a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.